Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 342

1.

Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.

Fang H, He R, Chiu A, Viswanatha DS, Ketterling RP, Patnaik MS, Reichard KK.

Am J Clin Pathol. 2020 Jan 16. pii: aqz206. doi: 10.1093/ajcp/aqz206. [Epub ahead of print]

PMID:
31977035
2.

The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm.

Ravindran A, He R, Ketterling RP, Jawad MD, Chen D, Oliveira JL, Nguyen PL, Viswanatha DS, Reichard KK, Hoyer JD, Go RS, Shi M.

Blood Cancer J. 2020 Jan 23;10(1):7. doi: 10.1038/s41408-020-0275-8.

3.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.

Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM.

Br J Haematol. 2020 Jan 16. doi: 10.1111/bjh.16380. [Epub ahead of print]

PMID:
31945802
4.

High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?

Pophali PA, Marinelli LM, Ketterling RP, Meyer RG, McPhail ED, Kurtin PJ, Mwangi R, Maurer MJ, Habermann T, King RL.

Blood Cancer J. 2020 Jan 13;10(1):5. doi: 10.1038/s41408-019-0271-z.

5.

Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia.

Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, Litzow MR, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM.

Am J Hematol. 2020 Mar;95(3):E68-E72. doi: 10.1002/ajh.25729. Epub 2020 Jan 26. No abstract available.

PMID:
31919873
6.

Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.

Blackburn PR, Huang L, Dalovisio A, Pitel BA, Chen D, Oliveira JL, Wood AJ, Smadbeck JB, Johnson SH, Vasmatzis G, Haferlach C, Greipp PT, Hoppman NL, Ketterling RP, Baughn LB, Peterson JF.

Cancer Genet. 2020 Feb;241:67-71. doi: 10.1016/j.cancergen.2019.12.005. Epub 2019 Dec 26.

PMID:
31902694
7.

Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.

Smadbeck J, Peterson JF, Pearce KE, Pitel BA, Figueroa AL, Timm M, Jevremovic D, Shi M, Stewart AK, Braggio E, Riggs DL, Bergsagel PL, Vasmatzis G, Kearney HM, Hoppman NL, Ketterling RP, Kumar S, Rajkumar SV, Greipp PT, Baughn LB.

Blood Cancer J. 2019 Dec 16;9(12):103. doi: 10.1038/s41408-019-0255-z.

8.

Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies.

Schultz MJ, Blackburn PR, Cogbill CH, Pitel BA, Smadbeck JB, Johnson SH, Vasmatzis G, Rech KL, Sukov WR, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF.

Leuk Lymphoma. 2019 Dec 6:1-4. doi: 10.1080/10428194.2019.1699081. [Epub ahead of print] No abstract available.

PMID:
31809670
9.

Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens.

Khurana S, Melody ME, Ketterling RP, Peterson JF, Luoma IM, Vazmatzis G, Tun HW, Foran JM, Jiang L.

Cancer Genet. 2020 Jan;240:40-44. doi: 10.1016/j.cancergen.2019.11.002. Epub 2019 Nov 9.

PMID:
31739126
10.

Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen.

Dalland JC, Meyer R, Ketterling RP, Reichard KK.

Am J Clin Pathol. 2020 Feb 8;153(3):333-341. doi: 10.1093/ajcp/aqz168.

PMID:
31671434
11.

Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma.

Skala SL, Ye JC, Stumph J, Macon WR, Quinones FR, Khachaturov V, Ketterling RP, Dewar R.

Clin Pathol. 2019 Sep 29;12:2632010X19878410. doi: 10.1177/2632010X19878410. eCollection 2019 Jan-Dec.

12.

Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion.

Rowsey RA, Smoley SA, Williamson CM, Vasmatzis G, Smadbeck JB, Ning Y, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF.

Blood Cancer J. 2019 Oct 1;9(10):81. doi: 10.1038/s41408-019-0239-z.

13.

Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing.

Peterson JF, Pearce KE, Meyer RG, Greipp PT, Knudson RA, Baughn LB, Ketterling RP, Feldman AL.

Histopathology. 2020 Feb;76(3):481-485. doi: 10.1111/his.14005. Epub 2020 Jan 17.

PMID:
31557339
14.

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.

Leukemia. 2020 Feb;34(2):656-661. doi: 10.1038/s41375-019-0574-x. Epub 2019 Sep 11. No abstract available.

PMID:
31511613
15.

Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy.

Peterson JF, He RR, Nayer H, Cuevo RS, Smadbeck JB, Vasmatzis G, Greipp PT, Ketterling RP, Hoppman NL, Baughn LB.

Cancer Genet. 2019 Sep;237:51-54. doi: 10.1016/j.cancergen.2019.06.007. Epub 2019 Jun 12.

PMID:
31447065
16.

Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS.

Acta Haematol. 2019;142(4):224-232. doi: 10.1159/000500164. Epub 2019 Jul 23.

PMID:
31336367
17.

Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation.

Peterson JF, Meyer RG, Smoley SA, Webley M, Smadbeck JB, Vasmatzis G, Pearce K, Greipp PT, Ketterling RP, Craig FE, Stewart AK, Baughn LB.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):598-602. doi: 10.1016/j.clml.2019.06.006. Epub 2019 Jun 18. No abstract available.

18.

Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma.

Peterson JF, Blackburn PR, Webley MR, Pearce KE, Williamson CM, Vasmatzis G, Smadbeck JB, Bieliauskas SL, Reichard KK, Ketterling RP, Baughn LB, Greipp PT.

Mayo Clin Proc. 2019 Jul;94(7):1381-1384. doi: 10.1016/j.mayocp.2019.04.030. No abstract available.

PMID:
31272582
19.

Impact of acquired del(17p) in multiple myeloma.

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530.

20.

Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements.

Peterson JF, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Ketterling RP, Macon WR, Baughn LB.

Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3). pii: a004077. doi: 10.1101/mcs.a004077. Print 2019 Jun.

21.

Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, Kadin ME, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell SM, Feldman AL.

Blood. 2019 Jun 27;133(26):2776-2789. doi: 10.1182/blood.2019000626. Epub 2019 May 17.

PMID:
31101622
22.

Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies.

Tefferi A, Nicolosi M, Penna D, Vallapureddy R, Hanson CA, Pardanani A, Gangat N, Ketterling RP.

Leukemia. 2019 Oct;33(10):2522-2553. doi: 10.1038/s41375-019-0453-5. Epub 2019 May 1. No abstract available.

PMID:
31040370
23.

ADDENDUM: Section E9 of the American College of Medical Genetics Technical Standards and Guidelines: Fluorescence in situ hybridization.

Mascarello JT, Hirsch B, Kearney HM, Ketterling RP, Olson SB, Quigley DI, Rao KW, Tepperberg JH, Tsuchiya KD, Wiktor AE; A Working Group of the American College of Medical Genetics (ACMG) Laboratory Quality Assurance Committee.

Genet Med. 2019 Oct;21(10):2405. doi: 10.1038/s41436-019-0508-z. No abstract available.

PMID:
31028353
24.

Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies.

Peterson JF, Baughn LB, Ketterling RP, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Mangaonkar AA, Thompson CA, Parikh SA, Chen D, Viswanatha DS.

Blood Adv. 2019 Apr 23;3(8):1298-1302. doi: 10.1182/bloodadvances.2019031450. No abstract available.

25.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
26.

Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia.

Peterson JF, Pitel BA, Smoley SA, Smadbeck JB, Johnson SH, Vasmatzis G, Koon SJ, Webley MR, McGrath M, Bayerl MG, Baughn LB, Rowsey RA, Ketterling RP, Greipp PT, Hoppman NL.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003533. doi: 10.1101/mcs.a003533. Print 2019 Apr.

27.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

28.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
29.

A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia.

Peterson JF, Ketterling RP, Huang L, Finn LE, Shi M, Hoppman NL, Greipp PT, Baughn LB.

Genes Chromosomes Cancer. 2019 Sep;58(9):665-668. doi: 10.1002/gcc.22744. Epub 2019 Mar 18.

PMID:
30790375
30.

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.

Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, Kumar S, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB.

Blood Cancer J. 2019 Feb 19;9(3):20. doi: 10.1038/s41408-019-0182-z. No abstract available.

31.

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Br J Haematol. 2019 Apr;185(2):254-260. doi: 10.1111/bjh.15800. Epub 2019 Feb 15.

PMID:
30768679
32.

Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.

Peterson JF, Sukov WR, Pitel BA, Smoley SA, Pearce KE, Meyer RG, Williamson CM, Smadbeck JB, Vasmatzis G, Hoppman NL, Greipp PT, Baughn LB, Ketterling RP.

Genes Chromosomes Cancer. 2019 Aug;58(8):567-577. doi: 10.1002/gcc.22741. Epub 2019 Mar 19.

PMID:
30707474
33.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y.

34.

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 May;94(5):E117-E120. doi: 10.1002/ajh.25420. Epub 2019 Feb 6. No abstract available.

PMID:
30680770
35.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

36.

Calculator-free point-of-care prognostication in myelodysplastic syndromes.

Tefferi A, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Apr;94(4):E99-E101. doi: 10.1002/ajh.25400. Epub 2019 Jan 24. No abstract available.

PMID:
30637785
37.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

38.

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Apr;94(4):424-430. doi: 10.1002/ajh.25391. Epub 2019 Jan 8.

PMID:
30592078
39.

False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.

King RL, McPhail ED, Meyer RG, Vasmatzis G, Pearce K, Smadbeck JB, Ketterling RP, Smoley SA, Greipp PT, Hoppman NL, Peterson JF, Baughn LB.

Haematologica. 2019 Jun;104(6):e248-e251. doi: 10.3324/haematol.2018.207290. Epub 2018 Dec 6. No abstract available.

40.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2019 Mar;94(3):286-290. doi: 10.1002/ajh.25351. Epub 2018 Dec 5.

PMID:
30516867
41.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

PMID:
30516848
42.

Constitutional chromosome rearrangements that mimic the 2017 world health organization "acute myeloid leukemia with recurrent genetic abnormalities": A study of three cases and review of the literature.

Peterson JF, Pitel BA, Smoley SA, Smadbeck JB, Johnson SH, Vasmatzis G, Pearce KE, He R, Kelemen K, Al-Mondhiry HAB, Lamparella NE, Hoppman NL, Kearney HM, Baughn LB, Ketterling RP, Greipp PT.

Cancer Genet. 2019 Jan;230:37-46. doi: 10.1016/j.cancergen.2018.11.005. Epub 2018 Nov 20. Review.

PMID:
30497985
43.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.

44.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3. No abstract available.

45.

Genetic predictors of response to specific drugs in primary myelofibrosis.

Penna D, Szuber N, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4. No abstract available.

46.

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Szuber N, Lavu S, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5. No abstract available.

47.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

48.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.

Am J Hematol. 2019 Jan;94(1):111-117. doi: 10.1002/ajh.25333. Epub 2018 Nov 15.

49.

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.

Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Leukemia. 2019 Mar;33(3):780-785. doi: 10.1038/s41375-018-0283-x. Epub 2018 Oct 12. No abstract available.

PMID:
30315236
50.

Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.

Aypar U, Smoley SA, Pitel BA, Pearce KE, Zenka RM, Vasmatzis G, Johnson SH, Smadbeck JB, Peterson JF, Geiersbach KB, Van Dyke DL, Thorland EC, Jenkins RB, Ketterling RP, Greipp PT, Kearney HM, Hoppman NL, Baughn LB.

Eur J Haematol. 2019 Jan;102(1):87-96. doi: 10.1111/ejh.13179. Epub 2018 Nov 22.

PMID:
30270457

Supplemental Content

Loading ...
Support Center